* License to formulation technology with BDD Pharma, UK
SMOL = Small Molecule; Oligo = Oligonucleotides; FCCM = Familial cerebral cavernous malformations
Recent News
October 20, 2025
Lundbeck and Contera Pharma announce research collaboration to advance RNA-targeting medicines for serious neurological conditions
Valby, Denmark, 20 October 2025 – H. Lundbeck A/S (Lundbeck) and Contera Pharma today announced a strategic research collaboration aiming to accelerate the…
Read more
September 17, 2025
Contera Pharma announces positive topline results in Phase 1b trial of CP-012, a novel therapy to treat nocturnal immobility and morning akinesia in Parkinson’s disease
Hørsholm, September 17, 2025 - Contera Pharma A/S, a clinical-stage biotech company pioneering innovative treatments for neurological disorders, has announced positive topline…
Read more
Contact us
Contera Pharma
Contera Pharma A/S
Venlighedsvej 4
2970 Hørsholm
Denmark
Thomas Sager, CEO
info@conterapharma.com